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ABSTRACT
This research describes how the FDA has incorporated risk analysis methodology into its
inspection of pharmaceutical manufacturers in the time period between 2004-2008. It analyzes
the violations specified in FDA warning letters that are issued after site inspections of
pharmaceutical facilities. The outcome of this analysis is to evaluate the FDA’s performance to
determine whether it has improved the overall inspection process and increased its quality
assurance.
U.S.A. FOOD AND DRUG ADMINISTRATION
This paper outlines an initial investigation of the FDA’s new risk methodology as it is applied to
the manufacturing sector of the bio-pharmaceutical (BP) industry. The research reviewed FDA
regulations concerning quality assurance, the corresponding procedural manuals, as well as,
examining the violation warning letters issued by the FDA from 2004 to 2008. This research
will serve as the basis for developing a more formal research proposal to study in-depth changes
in the FDA as well as the BP industry.
In 2004, the FDA announced that its oversight of the BP industry would incorporate a risk-based
methodology in its inspection of manufacturing processes. In the almost 5 years between the
2004 announcement and 2008, questions have arisen as to how this decision has impacted the
FDA oversight process, in terms of manufacturing sites inspected, types of observations
completed at each site, and outcomes of these inspections. Knowing this information is basic to
understanding how risk methodology is incorporated into manufacturing site visits on one hand,
and on the other how successful this new approach has been for the FDA (Adis, 2007). This
study gathered data from site visits, categorized the number and type of annual manufacturing
inspections, and examined the frequency and type of violations detailed in the warning letters
issued to manufacturers. As far as evaluating the success of this new approach, the data looked
at the FDA’s performance and whether it has been more capable of finding violations in the
inspection process, and better at providing directions and guidance to manufacturers during this
time period.
Gathering this information is both a significant and complex task, considering the thousands of
inspections that occur at diverse manufacturing facilities around the country. Yet this task has
been made somewhat easier by the Freedom of Information Act which makes important data
available to researchers and the BP community. The problem quickly becomes that of sorting
through the vast amount of information available at the FDA web site, which details the full
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operation of the Agency. Therefore, the researchers made the decision to focus on one particular
subset within the BP industry – that of medical device manufacturers. Within this industry
subset, the research then established benchmark indicators showing how the risk methodology
has been incorporated into the FDA current Good Manufacturing Practices (cGMP). Specifically
this paper reviews and analyzes how quality assurance and CAPA risk methodology (as detailed
in FDA regulation 820.100) is incorporated within the FDA rubric of cGMP. CAPA is a critical
component in measuring risk, since problem containment and remediation are intrinsic in
determining the outcome (COSO, 2004).
The choice of focusing on one FDA cGMP sector – that of medical device manufacturing –
enables a comparison to be made between similar manufacturing sites, while using the same
FDA inspection methodologies. Therefore it becomes easier to judge how the FDA incorporates
CAPA and quality assurance in its emphasis on manufacturing excellence. This research
provides an initial cut at evaluating the risk methodology and providing measurement data to
determine how and with what success the Agency performs its oversight function.
FDA’S CURRENT GOOD MANUFACTURING PRACTICES METHODOLOGY
The main objective of the FDA is to ensure public safety through establishing industrial quality
standards, benchmarks and vigorous oversight. Its role is that of principal supervisory Agency,
assuring that industry best practices are followed (GAMP, 2001) in the research, development
and manufacturing life cycle of drugs, vaccines, other biological products, and medical devices.
Its tasks are to inspect sites, examine products and processes, issue warning letters, and order
recalls. The exceptionally low tolerance for variability or deviation in quality pharmaceutical
products is built around its compliance guidelines (FDA, 2003a; FDA, 2004a).
The FDA has chosen to add to its best practice methodology a new risk-based paradigm for
achieving its oversight objectives and managing its inspection tasks (de Neufville, 2004). This
decision came from the fact that the FDA’s own internal reviews made it clear that limited
budgets, lack of staff and insufficient resources prevented it from meeting its goals of inspecting
domestic BP facilities within a 2 or 4 year cycle, depending on type of products and processes
used in the manufacturing. Coupled with this is the knowledge that the situation can only get
worse as the number of BP research and production sites keeps increasing, while FDA resources
remain relatively unchanged. The inevitable outcome is that the number of FDA visits and
inspections would remain at approximately the same level, resulting in an increasing and
untenable backlog. To resolve this situation the FDA chose a different methodology that orders
and prioritizes inspection sites based on their associated risk (FDA, 2004b). This transition
began in 2004-2005 when the Agency adopted this new risk-based methodology, outlined in part
by the Pharmaceutical Current Good Manufacturing Practices (cGMP) for the 21st Century
(FDA, 2004a).
This methodology guides the tasks of choosing which manufacturing sites have the highest
priority, how the site inspection process is carried out, and whether warning letters and recalls
are necessary (FDA, 2008a). “The model is based on a risk-ranking and filtering method that is
well-recognized, objective, and rigorously systematic. This approach should help the Agency
make the best use of its limited surveillance and enforcement resources, while maximizing the
impact of those resources on the public health” (FDA, 2004a).
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Therefore, in addition to normally scheduled inspections, the FDA now schedules site visits by
prioritizing those manufacturing facilities that have a previous history of violations, or perform
processes that have an inherent risk of system failure. The Agency includes CAPA requirements
regarding the need for systems that monitor performance and can correct and remediate
anomalies (ICH, 2005). The FDA inspectors’ task is to ensure that these monitoring and
remediation systems are in place. The FDA then has necessary feedback from the BP industry to
update its quality assurance database concerning the frequency and severity of events associated
with different production practices (FDA, 2008c). The FDA applies this risk methodology to
filter and prioritize the data to focus on those that represent the greatest hazard. This is
accomplished by using risk management statistics in combination with the industries best
business practices. The FDA can then compare this information with its overall industry risk
guidelines. On this basis, the FDA can build a performance history for each manufacturer and
then schedule site visits and evaluations focusing on these key risk indicators (ICH, 2007).
WARNING LETTERS
The FDA uses the quality assurance and risk method regulations as the basis of facility
inspections. The results of the site visit are recorded on Inspection Form 483. The next step is
for the Agency’s regional offices to examine the key performance indicators found in the 483
forms and issue warning letters (WLs) where there are violations and deficiencies. These
warning letters, which are available online through the Freedom of Information Act (FOIA,
2008), provide a window for seeing into the cGMP and its risk methodology, for they summarize
the inspection process for those firms that are in violation. A study of several years’ worth of
WLs can serve as a baseline in determining the Agency’s overall oversight performance, by
examining the WLs issued, and determining their scope and depth. In addition, a review of the
WLs may be helpful in analyzing which factors the FDA wants to emphasize in its future
inspections. These factors may be related to a particular risk issue, but can also indicate general
FDA policies.
Table 1 offers an initial guide to the contents of a warning letter. It is an abbreviated composite
based on the review of hundreds of WLs issued between 2004 and 2008. The outline uses FDA
language and frequently quotes from the regulations, making it in many instances awkward to
read. This also may be the result of a computer program called EIR Turbo which takes the
contents of Form 483 and automatically produces the WL (EIR, 2008).
Table 1 has two columns. The first lists the topics frequently found in many cGMP WLs. The
second column lists the corresponding 820 regulation that is being cited. For our research
purposes the topics can be divided into two groups: CAPA (820.100) and those other 820
regulations that address quality assurance.
RESEARCH
The research examined the warning letters issued by the FDA in the time period 2003-2008 that
specifically dealt with cGMP, quality assurance and CAPA. As mentioned in the previous
section, the research looked into the WLs to determine to what degree CAPA was integrated into
cGMP inspection methodology. Using the Freedom of Information Act, the research was able to
review hundreds of WLs that met the following criteria:
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Table 1: Warning Letter Guide.
Warning Letter Topics

Inadequate Response
Failure to ensure that an adequate and effective quality
system exists throughout the organization
Quality audits did not assure that the firm's quality
system is in compliance
Failure to adequately establish and maintain procedures
for implementing CAPA.
Incomplete documentation of CAPA activities
Failure to adequately analyze quality data sources, or
identifying existing and potential causes of
nonconforming product or other quality problems
Failure to adequately implement procedures for
receiving, reviewing, and evaluating complaints
•
•
•

cGMP for Medical
Devices (CFR), Part
820
Form FDA 483, List of
Inspection Observations
21 CFR § 820.20
21 CFR § 820.22
21 CFR § 820.100(a)
21 CFR §820.100(b)
21 CFR § 820.100(a1).

21 CFR § 820.198

Issued in 2003-2008 time frame
Subject was cGMP found in regulations 501(h) of the Act (21 U.S.C. §351(h))
Included FDA regulations section 820, Quality System, and its subpart CAPA risk
methodology, 820.100.

Table 2 shows the total number of inspections per year that the FDA performed at facilities that
manufactured medical devices. In addition the table shows the total number of WLs that were
issued based on violations at those sites. These data were was reviewed in conjugation with the
FDA document 2008 FDA’s Field Activities – Office of Regulatory Affairs (FDA, 2008b) and
other congressional reports (Crosse, 2008). These reports to Congress contain very useful data
including budgetary and staffing information and field activities. Using these resources, it was
straightforward to determine the total number of field inspections per year, as well as those that
triggered WLs. It should be noted that the field manual and inspection guidelines indicated that
site visits were generally of two kinds. The first took place because it was a routinely scheduled
inspection, or in some instances was a follow-up to ensure that a previous deficiency had been
rectified. In this category few violations should be anticipated. The second type of visit was
based on risk factors associated with certain pharmaceutical manufacturing processes, and plants
with site violation histories.
Reviewing the data in the table several trends are noticeable. The first is the decrease in total
number of inspections, moving from 1,736 in 2003 to 1,362 in 2007. This represents a drop of
374 site inspections, or 22% over 5 years. (The data for 2008 is not currently available, yet
preliminary information from various reports seems to indicate that it will be in the range of
1,250.) This decrease of 22% is in keeping with FDA statements concerning their limited staff,
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budget and resources that prevent the Agency from keeping up with the inspection of
manufacturing sites.
Table 2: Inspections of Manufacturing Sites producing Medical Devices.
Year
2003
2004
2005
2006
2007
2008

(A)
Total
Inspections
1,736
1,631
1,471
1,501
1,362
n/a

(B)
cGMP
WLs
95
121
127
142
136
162

(C)
Percent
(B/A)
5.5%
7.4%
8.6%
9.5%
10.0%
n/a

The next column (B) focuses on inspections that resulted in WLs being issued for cGMP
violations. During the time period 2003 to 2008, the WLs in this category increased from 95 to
162, or 71%. While the percentage seems significant, the actual numbers involved in the increase
was only 67 WLs, not a very large amount. The last column shows the gradual shift towards
increasing emphasis on cGMP as a subject for violation in the WLs over the 5 year time frame.
The research then further analyzed the same cGMP WL data to see how many emphasized
quality assurance and CAPA regulations. This more granular analysis is important because it
addresses whether the FDA is actually emphasizing the CAPA regulations which are
fundamental to risk analysis. This task was done by searching the WLs for those that focused
on Subchapter H--Medical Devices, Part 820 Quality System Regulation which also includes
CAPA 820.100.
Table 3 shows the total number of cGMP warning letters that cite Part 820 and CAPA (820.100).
The first column (A) of this table, cGMP WLs, is taken from Column B of Table 2. (It does not
include the year 2003 since this was before the switch over to cGMP.)The next column (B)
reviews those WLs to see if inspectors cited Part 820 Quality System Regulation violations. This
column shows a decrease in Part 820 WLs, except for a small uptick in 2008 due to the large
number of inspections that year. Column C shows that 820 quality assurance violations
decreased from 98% to 56% of all cGMP WLs. So while there was an overall increase in the
number of cGMP WLs during this period, there was a significant decrease in percentage of those
that addressed 820 violations. This means that inspectors and their district offices focused on
issues other than quality assurance and risk. These might include such factors as dirty premises,
food lacking refrigeration, fire safety, and a myriad of other cGMP regulations outside of 820,
such as pharmaceutical drug violations (21 Part 210, 211)
As mentioned earlier, CAPA (820.100) risk methodology is a subpart of the 820 quality systems
regulations, and columns D-F highlight this relationship. Column D shows the actual decline in
WLs that make specific references to CAPA violations (820.100). Column E shows this as a
percentage decline of WLs that cite CAPA violations (D/A). Column F provides a different
perspective, showing that a rather steady percentage (65-76%) of 820 warning letters focused on
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820.100 CAPA during the time period. Those cGMP WL and 820 WL that did not reference
CAPA, instead focused on other issues within the cGMP rubric, such as devices or services that
were lacking pre-market approval, misbranded items, poor packing or storage, and the like.
Table 3: cGMP WLs and those that specifically cite Part 820 and CAPA (820.100).
Year

(A)
cGMP
WLs

2004
2005
2006
2007
2008

121
127
142
136
162

(B)
820
WLs
119
109
89
82
90

(C)
(D)
(E)
(F)
Percen 820.10 Percent Percent
t
0
(D/A)
(D/B)
(B/A)
WLs
98%
91
77%
76%
86%
72
57%
66%
63%
58
41%
65%
60%
55
40%
67%
56%
62
38%
69%

Without belaboring the point, the WL data indicates that 820 and CAPA are not as dominant as
one might expect, given the FDA statements over the years about its movement to a new risk
based methodology. Based on data in this table, it is correct to say that 820 and CAPA are
frequently used regulations but they have not in fact dramatically changed the actual number of
cGMP WLs. In fact both Part 820 and CAPA show a generally decreasing influence on cGMP
WLs.
EXAMINATION OF 820 AND CAPA 820.100
In further examining the role of CAPA within the 820 WLs, the research focused on 820.100
violations and calculated how frequently they were cited. This information gives an insight into
the practical working of the FDA risk methodology as it applies to 820 quality assurance
regulations.
As a first cut through the WL data, the research focused on two years, 2005 and 2008. The
reason for this choice is straightforward. 2005 was the first full year that the new methodology
was used by the Agency, while 2008 has the most current available data for the researchers to
use. Only 2 years were chosen for multiple reasons. The first is to become familiar with the WL
data and to work out a satisfactory method for reviewing and analyzing the data. The second is
that it takes significant time to go through the several pages that make up each WL and
categorize the salient features. Therefore this initial research served as a pilot study, testing the
approach and the findings to determine if they needed further exploration.
Table 4 and Table 5 focus on how CAPA is incorporated into WLs for 2005 and 2008. Table 4
lists the full set of CAPA regulations (820.100) and the number of manufacturing sites that were
in violation. For instance in 2008, CAPA violation 820.100a was cited in 40 out of the 62 WLs.
By contrast in 2005, 820.100a was cited in 28 of the 72 WLs. This is followed by Table 5 which
places the CAPA regulations in order of the most frequently cited regulations.
One of the most interesting findings in these 2 tables is the fact that some regulations are
frequently referenced (820.100a, a1, a3, b) in both years, while others are rarely used

Communications of the IIMA

6

2009 Volume 9, Issue 1

Analysis of FDS’s Risk Assessment Methodology

Adis

(820.100a5, a6, a7). Those that are frequently referenced make sense in that they call for reports,
statistics, actions needed, and documentation. Of those that are infrequently cited, it is
significant that management review (a7) has such a poor showing, since management is so
intrinsic to CAPA activities.
Table 4: CAPA regulations cited in WLs for years 2005 and 2008.
CAPA

Description

820.100 a

CAPA General Procedures,

820.100 a1

CAPA Processes, Reports, Statistical
Methods
CAPA Investigations

820.100 a2
820.100 a3

820.100 a6

CAPA Identification of Action
Needed
CAPA Verification and Validation of
Effectiveness
CAPA Implementations and
Modifications
CAPA dissemination of information

820.100 a7

CAPA Management Review

820.100 b

CAPA Activities/Documentation

820.100 a4
820.100 a5

2008
2005
%
CASES CASES Change
n=62
n=72
40
28
65%
40%
+25%
16
29
26%
40%
-14%
8
13
13%
18%
-5%
14
21
23%
29%
-6%
10
17
16%
24%
-8%
9
6
15%
8%
+7%
4
11
6%
7%
-1%
2
4
3%
6%
-3%
12
24
19%
33%
-14%

Table 5: Most Cited CAPA Regulations in 2005 and 2008.
Order
1
2
3
4
5

2008
(%)
2005
(%)
820.100 n=62 820.100 n=72
a
65%
a
40%
a1
26%
a1
40%
a3
23%
b
33%
b
19%
a3
29%
a4
16%
a4
24%

Both Tables 4 and 5 clearly show a general trend away from citing CAPA regulations in the WLs
between 2005 and 2008. Within Table 4, seven of the nine regulations show a decreased usage
between 2005 and 2008. Furthermore, five regulations show a decrease of more than 5
percentage points between these two years. The noteworthy exception is the increase in 2008
WLs that cite 820.100a which is CAPA general procedures. Table 5 shows a very large positive
increase in 100a citations, going from 40 % in 2005 to 65% in 2008. Even more surprisingly,
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additional research found that a large number of WLs only cited 820.100a violations and failed
to specifically cite any other CAPA regulation (100a1-a7, b). In 2005, 25% of the WLs only
referenced 100a to the exclusion of the other CAPA regulations, while in 2008 this increased to
39%.
It seems that the inspectors, in collaboration with their district offices, are using the 820.100a
regulation as an indicator of general CAPA weakness, rather than detailing more specific
violations CAPA regulations. It would be fair to say that this does not provide the level of
guidance that one might expect from the FDA, nor does it match the Agency’s stated emphasis
on a new risk methodology.
ADDITIONAL 820 QUALITY REGULATIONS
So far the discussion has focused on just CAPA, one subpart of the 820 regulations. It is
important now to broaden the analysis to the full set of 820 Quality Systems regulations, because
in many instances there are overlapping relationships between corrective and preventative
actions and the maintenance of quality.
Table 6: Part 820 Quality System Regulation.
820 Regulations Mentioned in WL
Subpart A--General Provisions
§ 820.1 - Scope.
§ 820.3 - Definitions.
§ 820.5 - Quality system.
Subpart B--Quality System Requirements
§ 820.20 - Management responsibility.
§ 820.22 - Quality audit.
§ 820.25 - Personnel.
Subpart C--Design Controls
§ 820.30 - Design controls.
Subpart D--Document Controls
§ 820.40 - Document controls.
Subpart E--Purchasing Controls
§ 820.50 - Purchasing controls.
Subpart F--Identification and Traceability
§ 820.60 - Identification.
§ 820.65 - Traceability.
Subpart G--Production and Process
Controls
§ 820.70 - Production and process controls.
§ 820.72 - Measuring, and test equipment.
§ 820.75 - Process validation.
Subpart H--Acceptance Activities
§ 820.80 - Device Acceptance.
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2005
n=62
n=72
n/a
n/a

44%
40%
24%

51%
39%
22%

48%

53%

21%

29%

35%

33%

<10%
<10%

<10%
<10%

32%
15%
27%

39%
17%
33%

39%

51%
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§ 820.86 - Acceptance status.
Subpart I--Nonconforming Product
§ 820.90 - Nonconforming product.
Subpart J--Corrective and Preventive
Action
§ 820.100 - Corrective and preventive
action.
Subpart K--Labeling and Packaging
Control
§ 820.120 - Device labeling.
§ 820.130 - Device packaging.
Subpart L--Handling, Storage,
Distribution,
§ 820.140 - Handling.
§ 820.150 - Storage.
§ 820.160 - Distribution.
§ 820.170 - Installation.
Subpart M--Records
§ 820.180 - General requirements.
§ 820.181 - Device master record.
§ 820.184 - Device history record.
§ 820.186 - Quality system record.
§ 820.198 - Complaint files.
Subpart N--Servicing
§ 820.200 - Servicing.
Subpart O--Statistical Techniques
§ 820.250 - Statistical techniques.

<10%

<10%

24%

29%

n/a

n/a

<10%
<10%

<10%
<10%

<10%
<10%
<10%
<10%

<10%
<10%
<10%
<10%

<10%
21%
23%
<10%
69%

<10%
22%
36%
<10%
61%

<10%

<10%

<10%

<10%

Table 6 displays the complete set of 820 subparts that make up Quality Systems. In addition,
this table shows the percentage of times each regulation was cited in the WLs issued in 2005 and
2008. In Subpart A (General Provisions) and Subpart J (CAPA) there are no percentages shown.
The reason for the former is that all WLs cite Subpart A to generally describe the need for the
WL. The reason for the latter is that this pilot study examined only WLs that cited 820.100;
therefore it was not applicable to note the percentage, since by design it was 100%.
One of the interesting findings in Table 6 is the fact that some regulations are frequently cited in
both years, while others are rarely. Those 820 regulations that are frequently referenced are
complaint monitoring (198), design controls (30), management responsibility (20), quality audit
(22), and product acceptance (80). However, some might find it strange that statistical techniques
(250) was cited in less than 10 percent of the cases, since the inspections concern the
determination of quality assurance. (The actual percentage in 2005 was 7% of the cases,
decreasing to 5% in 2008).
Overall there seems to be a strong logical link between CAPA’s regulations and the WLs’ focus
on quality issues such as complaints (198) and on Subpart B quality system requirements (20, 22,
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25). This makes sense, since complaint tracking clearly links together with corrective measures,
and quality systems with preventive measures.
One potential disparity is noted between CAPA management review (100a7) and management
issues found in 820 Subpart B. CAPA management review (100a7) makes up only 3% of the
2008 WL cases, while Subpart B Management responsibility (20) is 44% of the 2008 WL cases.
It seems that given the choice, the WLs prefer to bring up management issues in terms of quality
requirements rather than CAPA.
Furthermore, in reviewing the general changes that took place between 2005 and 2008, Table 6
shows that ten of the fourteen regulations listed show a decrease. This means that these
regulations were cited fewer times in 2008. Three out of the remaining four showed minor
increases in usage. Only the complaint files regulation (198) shows a large increase, going from
61 % in 2005 to 69% in 2008. This is further elaborated in Table 7 which shows the most
frequently cited 820 regulations between 2005 and 2008. This table shows a similarity in order
ranking in the citations for the years 2005 and 2008, and again highlights the significance of 198
as the most often cited 820 regulation, the other being CAPA 100a (shown in Table 5).

Table 7: The most frequently cited 820 regulations between 2005 and 2008.
Order

1
2
3
4
5

2008
820
198
30
20
22
80

2008
(%)
69%
48%
44%
40%
39%

2005
820

2005
(%)

198
30
20
80
22

61%
53%
51%
51%
39%

After reviewing all the 820 regulations, it is clear that the trend in violations shown by the WLs
is downward, with the few exceptions mentioned above, and this is captured in Table 8.
Combining the results from this and the previous CAPA section, the two regulations that stand
out in 2008 are 820.100a (general procedures) cited in 65% of the WL and 820.198 (complaint
files) in 69%. The direction that the Agency seems to be frequently taking with 820 regulations
is to cite general CAPA violations (100a), and then use the example of failures in maintaining
adequate complaints procedures (198).
The Agency seems to be using complaints 820.198 as a proxy for overall quality on one hand
and to support the more general CAPA 820.100a on the other. It is certainly a possibility that the
Agency is focusing on this particular strongly related CAPA component as a way to build
compliance.
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Table 8: Changes of greater than 5% between 2005 and 2008 with 820.
820 Regulations
§ 820.20 - Management responsibility.
§ 820.30 - Design controls.
§ 820.40 - Document controls.
§ 820.70 - Production and process
controls.
§ 820.75 - Process validation.
§ 820.80 - Device Acceptance.
§ 820.90 - Nonconforming product.
§ 820.184 - Device history record.
§ 820.198 - Complaint files.

2008
n=62
44%
48%
21%
32%

2005
n=72
51%
53%
29%
39%

%
Change
-7%
-5%
-8%
-7%

27%
39%
24%
23%
69%

33%
51%
29%
36%
61%

-6%
-12%
-5%
-13%
+8%

DISCUSSION
It should be noted at the beginning of this discussion that the research methodology of analyzing
WLs has its limitations, and provides only one perspective on FDA performance. Other avenues
of research could be reviewing 483 observational inspection forms and written responses from
the manufacturer, as well as data about product recalls, fines and penalties. These other factors
are important, and may lead to a different understanding of the FDA inspection process. Clearly
more depth could be gained with a detailed comparison of the findings in the WLs with the FDA
inspection manuals and quality assurance guidelines (FDA, 2003b; FDA, 2003d; FDA, 2003e).
Furthermore, future research could possibly examine the strong likelihood that the WLs are
vetted by the FDA’s legal staff to prevent lawsuits claiming a biased inspection process
(Goldstein, 2008). Part of this WL vetting process as well as the sameness in style, format,
expressions, and perhaps even content, may be the result of the EIR Turbo computer software
that the FDA has used since 2002 to automate the process of report writing inspection reports
and WLs (EIR, 2008).
Similarly this research did not specifically review the WL data from the manufacturers
perspective, though it did gain insight through previous research into the pharmaceutical industry
(Macher & Nickerson, 2006; Adis, 2008). The manufacturers’ response letters have not been not
reviewed or analyzed, nor have the specific steps taken by manufacturers to comply with CAPA
and 820 regulations. At this stage of the research there have been only preliminary discussions
with manufacturers about quality assurance issues. Expanding the research to include
manufacturers makes sense, and will be explored in future studies now that this work has
established some baselines.
These limitations were kept in mind during this study and will in part be addressed as this
research continues to probe the issues of quality and risk found in the FDA methodologies. Yet
it seems fair to say that these initial findings can serve as a benchmark for understanding how the
FDA is responding in terms of policy and direction to their internal problem of limited resources
and staff, and the complexity of mandatory oversight.
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CONCLUSION
However, in spite of these research limitations, some preliminary conclusions can be drawn
based on the data in this study. The results clearly show that the FDA is doing less cGMP
inspections, is less focused on CAPA/quality assurance, and the work it does is of a more general
nature. This seems to be independent of other research results that indicate dramatic
improvements in manufacturing within the pharmaceutical industry in this period (Macher &
Nickerson, 2006).
This research provides some basic insight into the FDA cGMP process through the study of WLs
as an outcome of FDA regulations. It confirms several known trends within the FDA, and it
establishes its own initial benchmarks:
•
•
•
•
•

Fewer FDA inspections over the time period 2003-2008.
While more cGMP WLs issued, a smaller percentage addressed 820 quality assurance.
Similarly there was a downward trend in CAPA citation based WLs.
CAPA WLs became less specific, focusing on the general provisions found in 100a
Inspectors cited fewer 820 provisions, with an emphasis on complaints (198)

If the FDA is using the inspection process as a policy tool to wake up manufacturers to the need
for quality systems, then there is some logic to the more general and less specific approach to the
oversight process. But if the purpose of the inspections is FDA oversight, in a drive for quality
assurance, then it is less successful. By not detailing the specific inspection violations, the FDA
is not providing the necessary guidance to the industry. The CAPA risk methodology within the
820 quality assurance framework has the potential to focus on weaknesses within the
manufacturers’ production processes. With detailed WL information, manufacturers can be
guided to building superior CAPA systems to correct and prevent system failures. Yet without
rigorous inspections, it is likely that manufacturers will try to ‘game the inspections’ and meet
quality and CAPA standards through building of complaints files and the like. This can only be
avoided when the FDA invigorates its 820 inspections systems.
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